[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 16,525
Citations 0
Clinical Trials Update
May 26, 2020

No Benefit for Lopinavir–Ritonavir in Severe COVID-19

JAMA. 2020;323(20):1999. doi:10.1001/jama.2020.6793

Treatment with the HIV combination drug lopinavir-ritonavir did not accelerate recovery or improve mortality rates among hospitalized patients with severe coronavirus disease 2019 (COVID-19), a trial in the New England Journal of Medicine reported.

An HIV medication was no better than standard care for patients with severe coronavirus disease 2019.

Philip Marazzi, MD/sciencesource.com

The study’s 199 patients with confirmed severe acute respiratory syndrome coronavirus 2 infection were randomly assigned to receive standard care plus 400 mg of lopinavir and 100 mg of ritonavir twice a day for 14 days or standard care alone.

For both groups the time to clinical improvement—the primary end point—was a median of 16 days. Researchers stopped the intervention early for 13 patients who experienced mainly gastrointestinal adverse events.